Can MRI scans reveal how ANO5 muscle disease progresses?

NCT ID NCT05206617

Ongoing Knowledge-focused Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study follows adults with pathogenic variants in the anoctamin 5 gene, which causes a form of limb-girdle muscular dystrophy. Over three years, researchers will use whole-body MRI to measure changes in muscle fat content, and questionnaires to track fatigue and quality of life. The goal is to understand how the disease progresses and to identify reliable outcome measures for future clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could identify reliable ways to measure disease progression, which may help design future clinical trials for treatments.
What could go wrong: This is a small observational study, so results may not apply to all patients. It does not test any treatment, so it cannot directly lead to a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMB GIRDLE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression limb-girdle muscular dystrophy neuromuscular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIMB GIRDLE MUSCULAR DYSTROPHY NEUROMUSCULAR DISEASES

Contacts and locations

Locations

Copenhagen Neuromuscular Center

Copenhagen, Capital Region, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.